CEO
SP
Synerkine Pharma
The startup develops fusion proteins that target regulatory mechanisms involved in inflammatory and neuropathic pain, normalizing pain responses and inhibiting inflammation. This approach provides patients with access to pharmaceutical solutions that demonstrate efficacy in multiple pre-clinical models.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$20.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops fusion proteins that target regulatory mechanisms involved in inflammatory and neuropathic pain, normalizing pain responses and inhibiting inflammation. This approach provides patients with access to pharmaceutical solutions that demonstrate efficacy in multiple pre-clinical models.